The Seattle-based firm will focus on its SC291 and UP421 programs for B-cell mediated autoimmune diseases and type 1 diabetes, respectively, with multiple data readouts expected in the next two years.
The company is now concentrating its resources on advancing SC291, its anti-CD19 allogeneic CAR-T therapy, for the treatment of B-cell mediated autoimmune diseases (AID). This new focus has led to ...
The company is now concentrating its resources on advancing SC291, its anti-CD19 allogeneic CAR-T therapy, for the treatment of B-cell mediated autoimmune diseases (AID). This new focus has led to the ...
[Click here for information about joining the class action] On November 4, 2024, Sana issued a press release announcing that it "will suspend development of both SC291 in oncology and of SC379 ...
Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...
Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships ...
GLEAM trial for SC291 in B-cell mediated autoimmune diseases, and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect data from these studies in 2024 and/or 2025 Announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback